We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
BerGenBio has announced that the first COVID-19 patient was dosed with bemcentinib in a phase 2 trial to evaluate the drug as a potential treatment. Read More
HHS has expanded an existing partnership between its Biomedical Advanced Research and Development Authority (BARDA) and Emergent BioSolutions, awarding the Maryland company approximately $628 million to manufacture COVID-19 vaccines. Read More
Sixty percent of the public surveyed say they believe a treatment or vaccine for COVID-19 will be developed in just under a year. And once developed, 64 percent said they thought it would be less than a year before the public could begin receiving a COVID-19 treatment or vaccine. Read More
The highly politicized debate over whether hydroxychloroquine is or is not useful to COVID-19 patients appears to be far from over. A coalition of more than 180 doctors and researchers have signed an open letter questioning the findings of a study showing that hydroxychloroquine and chloroquine have no benefit in treating COVID-19 patients. Read More